Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27566594 | 0.86 | MAOB (0.41) | MAOBSLC6A2SLC6A4ALOX15SLC6A3 | |
| SCHEMBL1582016 | 0.78 | NPC1 (0.39) | — | |
| SCHEMBL1582095 | 0.78 | GCK (0.38) | LMNAHTTSLC6A2 | |
| SCHEMBL1581954 | 0.77 | GCK (0.40) | — | |
| SCHEMBL1581770 | 0.77 | GCK (0.40) | LMNAHTTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1581700 | 0.77 | HSD11B1 (0.42) | CYP2D6 | |
| SCHEMBL9825525 | 0.75 | AKR1C1 (0.46) | LMNAHTTAKR1C1SLC6A2SLC6A4 | |
| SCHEMBL4284677 | 0.75 | MAOB (0.47) | MAOBLMNAHTTAKR1C1SLC6A2 | |
| SCHEMBL28868714 | 0.75 | MAOB (0.66) | MAOBLMNAHTTAKR1C1SLC6A2 | |
| SCHEMBL5437376 | 0.75 | MAOB (0.47) | MAOBAKR1C1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | MAOB 214/4885LMNA 3456/4885HTT 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.